Project Grant R44CA302219
Award Date 9/18/25
Completion Date 8/31/27
Dollars Obligated $1.3M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $400,000 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to O2M Technologies LLC to develop a Multifunctional Imager (MFI) that can simultaneously acquire tissue oxygen pressure (pO2) and pH maps using electron paramagnetic resonance imaging (EPRI) techniques. The 12-month project aims to create a 25 MT Halbach-type permanent magnet, new multi-modal transmit-receive electronics, and the integrated MFI instrument. This...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,379,442 to Embiosys Inc. from September 2025 to August 2027 to develop and evaluate a novel wearable device that delivers induced electric field (IEF) therapy for the treatment of triple-negative breast cancer (TNBC). The key product being developed is a wearable, washable garment (camisole/tank-top) that can deliver low-intensity, intermediate frequency electromagnetic radiation...
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
- This $399,358 Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Cordance Medical Inc. aims to optimize a non-invasive focused ultrasound system, called the "NeuroAccess System," to enable liquid biopsies for brain tumor patients. The key objectives are to demonstrate the safety of repeatedly opening the blood-brain barrier, optimize the opening volume and technique in a rat glioma model, and confirm the system's ability to...
- This federal Project Grant award of $226,704 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to develop a novel nanoparticle heating system for cancer therapy. The project aims to use low-frequency ferromagnetic resonance to efficiently heat magnetic nanoparticles and deposit energy into cancer cells, while minimizing heating of surrounding normal tissue. The award was granted to the Dartmouth-Hitchcock Clinic, a non-profit...
- This $3,155,815 Project Grant award from the National Cancer Institute (NCI), under the CFDA 93.394 Cancer Detection and Diagnosis Research program, supports research to develop advanced magnetic resonance imaging techniques for non-invasive measurement of glutamate metabolism in glioblastoma brain tumors. The primary awardee is Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, which will leverage its expertise in medical research, imaging technologies, and...
- This Project Grant award for $249,417.00 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research federal grant program (CFDA 93.395) to support the development of a drug product called MT-125 for the treatment of recurrent high-grade glioblastomas (GBM). Glioblastoma is an aggressive and deadly form of brain cancer with a very poor prognosis. The award will fund preclinical studies and a Phase 0/1B dose escalation clinical trial of MT-125, a dual inhibitor of...
- This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $399,995 to Omnecoil Instruments, Inc. to conduct feasibility testing of a novel system for integrated endorectal MRI and in-bore biopsy of the prostate. The goal is to develop a faster, more efficient, and more accurate diagnostic test for the estimated 1.4 million men who develop prostate cancer each year. The study will recruit 30 men...
- This $997,410 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop non-invasive MRI-based techniques to detect and differentiate between the invasive neuronal (NEU) and glycolytic/plurimetabolic (GPM) subtypes of high-grade glioma brain tumors. The project leverages recent discoveries about these tumor subtypes' distinct microstructural, metabolic, and synapse profiles to enable more comprehensive tumor...
- The National Cancer Institute awarded Myolex, Inc. a $263,052 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop their proprietary MSCAN device leveraging Electrical Impedance Myography (EIM) technology. This project aims to apply EIM for the first time to detect and quantify cancer cachexia, a critical condition impacting half of all cancer patients. The MSCAN device provides a cost-effective, convenient alternative to traditional imaging techniques...